Skip to main content
SpringerLink
Log in

Phosphodiesterase Inhibitors

  • Living reference work entry
  • First Online:
Encyclopedia of Psychopharmacology

  • 175 Accesses

Synonyms

PDE inhibitors

Definition

There are 11 families of phosphodiesterases (PDEs; PDE1–PDE11), which degrade the second messengers cAMP and/or cGMP. The activity of PDEs can be selectively inhibited with drugs. The most widely known PDE inhibitor is sildenafil, which is one of the three PDE5 inhibitors approved for the treatment of erectile dysfunction and also arterial pulmonary hypertension. In addition, two PDE3 inhibitors are approved for treating congestive heart failure or intermittent claudication, respectively. Recently, one PDE4 inhibitor has been approved for the treatment of chronic obstructive pulmonary disease. At the moment, PDE inhibitors are explored as possible therapeutic CNS drug targets for memory loss (PDE1, PDE2, PDE4, PDE5, PDE9), Alzheimer’s disease (PDE3, PDE4, PDE5, PDE7, PDE9), Parkinson’s disease (PDE1, PDE4, PDE7), Huntington’s disease (PDE1, PDE4, PDE5, PDE10), anxiety (PDE2, PDE5), depression (PDE4), schizophrenia (PDE3, PDE10), pain (PDE4, PDE5), or...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ambriz-Tututi M, Velazquez-Zamora DA, Urquiza-Marin H, Granados-Soto V (2005) Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. Eur J Pharmacol 512:121–127

    Article  CAS  PubMed  Google Scholar 

  • Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520

    Article  CAS  PubMed  Google Scholar 

  • Brink CB, Clapton JD, Eagar BE, Harvey BH (2008) Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 115:117–125

    Article  CAS  PubMed  Google Scholar 

  • Chapman TM, Goa KL (2003) Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 3:117–138

    Article  CAS  PubMed  Google Scholar 

  • Cheng J, Grande JP (2007) Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med (Maywood) 232:38–51

    CAS  Google Scholar 

  • Esposito K, Reierson GW, Rong Luo H, Sheng Wu G, Licinio J, Wong ML (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 41:177–185

    Article  CAS  PubMed  Google Scholar 

  • García-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Sallés J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, García-Osta A (2013) Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 64:114–123

    Article  PubMed  Google Scholar 

  • Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol 204:167–192

    Article  CAS  PubMed  Google Scholar 

  • Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signaling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165:1288–1305

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lahu G, Nassr N, Hünnemeyer A (2011) Pharmacokinetic evaluation of roflumilast. Expert Opin 7:1577–1591

    CAS  Google Scholar 

  • Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367–374

    Article  CAS  PubMed  Google Scholar 

  • Liebenberg N, Harvey BH, Brand L, Wegener G, Brink CB (2012) Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats. Metab Brain Dis 27:337–340

    Article  CAS  PubMed  Google Scholar 

  • Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670

    Article  CAS  PubMed  Google Scholar 

  • Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Pérez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I, Martinez A, Carro E (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer’s disease. Neurobiol Aging 34:2133–2145

    Article  CAS  PubMed  Google Scholar 

  • Puzzo D, Sapienza S, Arancio O, Palmeri A (2008) Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 4:371–387

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 202:419–443

    Article  CAS  Google Scholar 

  • Sharma S, Kumar K, Deshmukh R, Sharma PL (2013) Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders. Eur J Pharmacol 714:486–497

    Article  CAS  PubMed  Google Scholar 

  • Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS (2011) Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. Int J Imp Res 23:109–114

    Article  CAS  Google Scholar 

  • Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL, Prickaerts J (2013) Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology 64:124–136

    Article  CAS  PubMed  Google Scholar 

  • Szatmari SZ, Whitehouse PJ (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev(1), CD003119

    Google Scholar 

  • Xu Y, Zhang HT, O’Donnell JM (2011) Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 204:447–485

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neuropsychology, University of Maastricht, 616, 6200, Maastricht, MD, The Netherlands

    Jos Prickaerts

Authors
  1. Jos Prickaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jos Prickaerts .

Editor information

Editors and Affiliations

  1. Section of Behavioural Pharmacology, King's College London Institute of Psychiatry P049, London, United Kingdom

    Ian P. Stolerman

  2. Brown Medical School, Butler Hospital, Providence, Rhode Island, USA

    Lawrence H. Price

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Prickaerts, J. (2014). Phosphodiesterase Inhibitors. In: Stolerman, I., Price, L. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27772-6_403-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27772-6_403-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-27772-6

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation